Swedish Orphan Biovitrum stock
SOBI.STSTOSwedish Orphan Biovitrum AB, HealthcareISIN SE0000872095
75Score 75 out of 100, Strong
Price and trend
82 / 100
Price history
+43% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 12% above it.
Since October 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 2.2% below its 52-week high. Largest decline in 20 years: 78% (February 2007 to November 2011).
Chart figures for advanced users
- SMA 50$45.33
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$43.48
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$31.79
- The lowest closing price of the last twelve months.
- Resistance$49.96
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Swedish Orphan Biovitrum AB belongs to the Medical (Pharmaceuticals) industry (Sweden) and, with a market value of $16.99B, is number 2 of 15 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.83B (up 8.5% year on year) and earnings of $47.93M (down 87.7%).
- For fiscal 2026, analysts expect on average revenue of $3.35B (up 18.3%) and adjusted earnings per share of $1.96 (up 1,311.4%).
Show more
- MEQIRI Score 75 out of 100 (Strong): rank 75 of 702 in Healthcare, median 53.
- The P/E is 25.8 (Medical (Pharmaceuticals) median 35.7, own median of recent years 25.3).
- Our model puts fair value at $67.22, with the price 27% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 27% below the fair value of $67.22.Valuation 73
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 85
- High marginNet margin 20.7% over the last 12 months, Medical (Pharmaceuticals) median 8.7%.Profitability 82
Weaknesses
- Earnings per share fallingDown 33.3% a year since 2020.
- Interest barely coveredOperating profit covers interest only 1 times.Stability 56
- DilutionShare count up 12% since 2020.Capital allocation 43
Its standout strengths are momentum and fundamentals, while capital allocation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 76 to 75.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
- price near its 52-week high
- calm price action
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $51.71 and expensive above $96.03 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $66.96 (cash-flow model) and $67.47 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $61.35, at 6.2% it would be $76.04.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (35.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 14.8% on the twelve months before. Revenue has grown strongly since 2006, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 44%, operating 29%, net 2%. Last 12 months: net 21%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Feb 2027in 83 days
- Last reported
- 27 Oct 2026EPS reported $0.65 (expected $0.60)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 6.8% since 15 Oct 2026.
- Earnings per share
- $1.96+2.5%
- Revenue
- $3.35B+0.4%
- Earnings per share
- $2.54+6.8%
- Revenue
- $3.83B+1.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +4.2%Sobi raised its 2026 revenue outlook to high teens to low 20s percent growth at constant exchange rates, up from mid to high teens previously. The adjusted EBITDA margin guidance remains unchanged.
“We anticipate revenue to grow at high teens to low 20s percentage at CER, and previously mid to high teens percentage.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
What happened at Swedish Orphan Biovitrum
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 75
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger and next smaller companies by market value
- Royalty PharmaRPRX $30.71B71
- JD Health International6618.HK $16.65B70
- Sino Biopharmaceutical1177.HK $12.58B65
- Recordati Industria Chimica e FarmaceuticaREC.MI $11.92B74
- Kyowa Kirin4151.T $8.4B77
- Corcept TherapeuticsCORT $8.07B75
- Kiniksa Pharmaceuticals InternationalKNSA $7.56B68
- Tsuruha Holdings3391.T $7.1B62
ETFs that hold Swedish Orphan Biovitrum
Held by 102 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.57% | 0.49% | €26.29M |
| iShares OMX Stockholm Capped UCITS ETFOM3X | 1.07% | 0.10% | €198.93M |
| iShares STOXX Europe Mid 200 UCITS ETF (DE)EXSD | 0.64% | 0.20% | €634.13M |
Show 5 more
| Xtrackers MSCI Nordic UCITS ETF 1DXDN0 | 0.59% | 0.30% | €1.19B |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 0.56% | 0.46% | €722.41M |
| iShares Ageing Population UCITS ETF2B77 | 0.53% | 0.40% | €813.42M |
| iShares MSCI Europe Mid-Cap Equal Weight UCITS ETFCEMT | 0.49% | 0.25% | €36.34M |
| Amundi MSCI Europe Ex EMU ESG Selection UCITS ETF Acc540H | 0.48% | 0.30% | €183.15M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.